Comparison of SF-36 scores of participants with residual limb pain with a VAS score ≥5 and participants with a VAS score <5. by Martin C. Berli (9427264)

Administration of anti-CD25 antibody decreases the early and late organ fungal burdens of resistant and susceptible mice. by Maíra Felonato (296591)

V5-SgG2 transfection in the epidermis modifies the termination site of peptidergic FNE. by Jorge Rubén Cabrera (685511)

Decreasing ShcA expression enhances TGF-β-induced Smad signaling. by Baby Periyanayaki Muthusamy (838234)

“…Note the enhanced basal pSmad3 or pSmad2 levels in cells transfected with ShcA siRNA. ShcA immunoblotting reveals decreased ShcA levels in cells transfected with ShcA siRNA, and GAPDH immunoblotting serves as loading control. …”

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

High concentrations of UA lead to decrease of TRACP 5b levels. by Zhi-Qi Wu (847506)

NG2 knockdown in GBM xenografts increased vascular reabsorption, decreased plasma volume and normalized tumour vasculature. by Jian Wang (5901)

Blocking CD88 decreased ANCA antigen translocation, ANCA-induced respiratory burst and degranulation in C5a-primed neutrophils. by Jian Hao (160736)

“…C and D: blocking CD88 decreased C5a-primed neutrophils for ANCA-induced respiratory burst. …”

Force analysis of a single rib. by Jianbo Jia (717814)

“…The simulation results show that for steps of 1mm, 2mm and 3mm height, the optimal polyline angle is concentrated in the range of 10°-11°, in which the Angle of 10.5° has a good performance against the steps of three heights. …”

Fig 4 - by Denise Wajnsztajn (3366902)

Klf5 activates the transcription of the eIF5a gene through direct binding to its promoter. by Dong Ma (584680)

Subjects:

Klf5 and eIF5a suppress Ang II–induced expression of NOX1 in VSMCs. by Dong Ma (584680)

Subjects:

Phlorizin decreased renal GTTR uptake, and increased serum drug levels <i>in vivo</i>. by Meiyan Jiang (438439)

Clone size distributions for all child patients. by John M. Murray (150672)

Subjects:

Clone size distributions for all adult patients. by John M. Murray (150672)

Subjects:

Clone size distributions at years 0.2, 4.8 and 11.4 years after the commencement of ART for Patient 1 of Maldarelli et al. by John M. Murray (150672)

Subjects:

Agent model of latency. by John M. Murray (150672)

Subjects:

Reservoir dynamics. by John M. Murray (150672)

Subjects:

Percentage of singletons and median clone size. by John M. Murray (150672)

Subjects:

Cells contributing to residual viremia. by John M. Murray (150672)

Subjects: